TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression by Galina Shmarina et al.
Shmarina et al. Journal of Translational Medicine 2013, 11:19
http://www.translational-medicine.com/content/11/1/19RESEARCH Open AccessTNF gene polymorphisms in cystic fibrosis
patients: contribution to the disease progression
Galina Shmarina1,2, Alexander Pukhalsky1*, Nika Petrova3, Ekaterina Zakharova4, Lucine Avakian1,
Nikolai Kapranov1 and Vladimir Alioshkin5Abstract
Background: It is well known that the disease progression in cystic fibrosis (CF) patients may be diverse in subjects
with identical mutation in CFTR gene. It is quite possible that such heterogeneity is associated with TNF-α and/or
LT-α gene polymorphisms since their products play a key role in inflammation. The aim of the study was to
investigate the possible roles of TNF gene polymorphisms in CF disease phenotype and progression.
Methods: 198 CF patients and 130 control subjects were genotyped for both TNF-α–308GA and LT-α + 252AG
polymorphisms.
Results: The carriers of the TNF-α–308A allele more frequently had asthma as compared to patients homozygous
for the TNF-α–308 G allele. In 9 of 108 (8.3%) of LTα + 252AA carriers, tuberculosis infection has been documented,
whereas there was no case of tuberculosis among patients, either homozygous or heterozygous for LTα +252 G
alleles (p = 0.01). We never observed virus hepatitis among LTα + 252GA carriers. The genotypes TNF-α–308GG – LT-α
+ 252AA and TNF-α–308GA – LT-α + 252AG were unfavorable with regard to liver disease development (both p < 0.05).
It was also shown that neutrophil elastase activity was higher in sputum specimens from high TNF producers with
genotypes TNF-α–308GA or LT-α + 252GG. In addition the carriers of such genotypes demonstrated a higher risk of
osteoporosis development (p values were 0.011 and 0.017, respectively).
Conclusions: The carriers of genotypes, which are associated with higher TNF-α production, demonstrated
increased frequency of asthma, higher levels of neutrophil elastase, and decrease of bone density. On the contrary,
the carriers of genotypes associated with low TNF-α production showed a higher frequency of tuberculosis
infection.
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The Major Histocompatibility Complex (MHC) contains
genes essential to both the adaptive and innate immune
systems. In humans, these genes are referred to as HLA
genes. Genes within the MHC traditionally divided into
three different subregions. Class I and II regions contain
genes encoded molecules that are responsible for antigen
presentation to T cells. The human Class III region is the
most gene-dense and highly conserved region of the
human genome [1]. Within this region TNF-α and TNF-β* Correspondence: osugariver@yahoo.com
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reproduction in any medium, provided the or(LT-α) genes are located close to each other [2]. The gene
products tumor necrosis factor (TNF)-α and TNF-β, also
known as lymphotoxin-α (LT-α), exhibit a broad spectrum
of inflammatory and immunomodulatory activities. In
particular, at the level of hypothalamus TNF-α stimulates
hypothalamic-pituitary-adrenal axis, in the liver it stimu-
lates acute phase response and increases insulin resistance
in different tissues. At the level of macrophages it stimu-
lates phagocytosis and the production of PGE2. In addition,
TNF-α is a potent chemoattractant, which helps neutro-
phils to stick to the endothelial cells for migration. The
effects of LT-α are similar substantially to
TNF-α, but LT-α is also important for the develop-
ment of lymphoid organs [3-5]. It is obvious that both
cytokines play an important role in pathogenesis of manyral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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most common autosomal recessive disease in Caucasian
population. Although there is no doubt that etiology of CF
is directly associated with the mutation in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene, it is
very difficult to connect the disease clinical course with the
type of mutation. Indeed, it is well known that CF progres-
sion may be diverse among either siblings or unrelated
patients with identical mutation in CFTR gene. Apparently
there are other factors including genetic ones, which may
determine the course of disease [6,7]. It is quite possible
that such heterogeneity is associated with TNF-α and/or
LT-α gene polymorphisms. A polymorphism in the
promoter region of the
TNF-α gene at nucleotide −308, relative to the transcrip-
tion start site, may be important in determining the host
TNF-α response [8]. There are two alleles at the poly-
morphic site, TNF-α–308 G and TNF-α–308A. In normal
population TNF-α–308 G homozygosity is the predominant
genotype. The TNF-α–308GA polymorphism has a small,
but significant, functional effect, with the A allele being
associated with higher constitutive and inducible levels of
transcription for TNF-α than the G allele [9]. Within
the first intron of the LT-α gene at position +252,
there is NcoI restriction polymorphism, consisting of
a Guanine (LT-α + 252 G) on one allele and an Adenine
(LT-α + 252Α) on the alternate allele. The presence of G at
this position defines the allele which is less frequent one in
white subjects and is associated with higher TNF-α
and TNF-β production [10,11]. Recently it has been
shown that lung function is significantly lower in CF
patients with TNF-α–308A polymorphism [12]. It has been
also demonstrated that certain TNF-α polymorphisms,
other than −308 G/A polymorphic loci, are also associated
with severity of CF lung disease in Czech and Belgian
patients [13].
The aim of the study was to investigate the possible roles
of TNF gene polymorphisms in CF disease phenotype and
progression. To address this issue, we genotyped 198 CF
patients and 130 control subjects for both TNF-α–308GA
and LT-α + 252AG polymorphisms.
Methods
Patients
A total of 198 patients (mean age, 12.7 ± 0.6 years) from the
Cystic Fibrosis Department of the Research Centre for
Medical Genetics (Moscow) were enrolled into the study.
CF was diagnosed by increased chloride concentrations
(>60 mmol/l) in a sweat test, typical clinical symptoms of
the disease, and/or detection of mutations in both CFTR
alleles. Clinical, biological and functional data were
obtained from hospital records from the previous 2 to
15 years. The data included date of birth, sex, CFTR
genotype, pulmonary function tests, nutritional status,airways microbiology, CF and non-CF complications
(cirrhosis, osteoporosis, pulmonary aspergillosis, asthma,
tuberculosis, virus hepatitis, etc.). Lung function was
assessed by spirometry in children >4 years during periods
of clinical stability. Respiratory microbial flora was deter-
mined by microscopy and culture of lower respiratory
tract secretions or throat swabs realized every routine visit
to the CF Department. Chronic airway colonization with
Pseudomonas aeruginosa was defined by the persistence
of the pathogen in at least three airway samples for at least
6 months. 127 individuals were chronically colonized with
the mucoid form of P. aeruginosa. The CFTR genotype in
138 CF patients was homozygous or heterozygous for
F508del (ΔF508). Forced expiratory volume in 1 sec
(FEV1) and forced vital capacity (FVC) values averaged
78.1 ± 4.4 and 70.1 ± 4.0% predicted, respectively. Charac-
teristics of patient groups with different TNF gene poly-
morphisms are presented in Additional file 1: Table S1
and Additional file 2: Table S2. The patients were treated
with basic therapy (mucolytics, multivitamins, high calorie
diet, microspheric enzymes). Some individuals received
anti-inflammatory therapy including azithromycin, nime-
sulide or/and prednisolone in low doses. In the case of
acute pulmonary exacerbation, antibacterial treatment
depended on the microbiology analysis of the sputum.
Individuals with P. aeruginosa infection were treated by
cephalosporins of third generation in combination with
aminoglycosids or ciprofloxacin.
Blood collection and sputum processing
Blood was collected in tubes with heparin (25 IU/ml) by
venipuncture. The sputum samples were placed into the
container with ice and delivered to the laboratory within
1 h. The weight of each sputum sample was calculated.
The same weight of phosphate-buffered saline without
Ca2+ and Mg2+ was added to the sputum sample. The
mixture placed on vortex for 10 sec and then on the
rocker for 30 min. The sample was filtered through a
100 μm filter to remove the mucus. The filtrate has been
centrifuged at 400 × g for 10 min at 4°C to pellet the
cells. The supernatant has been harvested, aliquoted and
stored at −60°C. Protein concentrations in the samples
were measured by Bradford’s method.
Genotyping
Genomic DNA was extracted from anti-coagulated blood
by a conventional proteinase K digestion/phenol-chloro-
form extraction method. Typing of TNF-α promoter gene
polymorphism (rs1800629, –308 G/A) was performed by
polymerase chain reaction (PCR) amplification (using a
50primer 50-AGGCAATAGGTTTTGAGGGCCAT30 and
50-TCCTCCCTGCTCCGATTCCG30 as the 30primer) and
NcoI digestion as described by Zhang DL et al. [14]. PCR
was carried out in 25-μL volume containing 0.5 μg of
Table 1 TNF gene polymorphisms in cystic fibrosis
patients and healthy children
Genotype Healthy children CF patients p
TNF-α–308GG 93 (72%) 145 (73%) 0.728
TNF-α–308GA 33 (26%) 53 (27%) 0.913
TNF-α–308AA 3 (2%) Not found 0.118
Allele frequency, G/A 0.85/0.15 0.87/0.13 0.921
LT-α + 252GG 13 (10%) 12 (6%) 0.272
LT-α + 252GA 42 (33%) 67 (36%) 0.633
LT-α + 252AA 72 (57%) 110 (58%) 0.854
Allele frequency, A/G 0.27/0.73 0.24/0.76 0.263
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polymerase, 0.2 mM of each 20-deoxiribonucleoside 50-tri-
phosphate, 67 mM Tris–HCl, pH 8.4, 2 mM MgCl2,
16.6 mM (NH4)SO4, and 20 μg/ml BSA. The cycling con-
dition consisted of an initial activation of Taq polymerase
at 94°C for 5 min followed by 35 cycles of denaturation at
94°C for 45 sec, annealing at 60°C for 45 sec, and exten-
sion at 72°C for 45 sec. The PCR products were digested
with 8 U of Nco I at 37°C for 6 h. Digested DNA
was analyzed on 8% polyacrylamide gels. Ethidium
bromide staining of the gel demonstrated the ori-
ginal 107 basepairs fragment (homozygous patients
for allele TNF-α–308A, lacking NcoI site), three frag-
ments of 102, 87 and 20 basepairs (heterozygous
patients), or two fragments of 87 and 20 basepairs of
size (homozygous patients for the allele TNF-α–308 G).
The Nco I polymorphism in intron 1 of the LT-α
(rs909253, +252 A/G) was determined by PCR-restriction
fragment length polymorphism method. A 782 basepairs
fragment of the LT-α genomic sequence, including the
polymorphic NcoI site, was amplified with a sense primer
(50- CCGTGCTTCGTGCTTTGGACTA 30) and an anti-
sense primer (50- AGAGGGGTGGATGCTTGGGTTC30)
[14,15]. PCR was carried out in 25-μL volume containing
0.5 μg of genomic DNA, 1 μM of each primer, 1.5 U
of Taq DNA polymerase, 0.2 mM of each 20-
deoxiribonucleoside 50-triphosphate, 67 mM Tris–HCl,
pH 8.4, 2 mM MgCl2, 16.6 mM (NH4)SO4, and 20 μg/ml
BSA. The cycling condition consisted of an initial activa-
tion of Taq polymerase at 94°C for 5 min followed by
35 cycles of denaturation at 94°C for 1 min, annealing at
50°C for 1 min, and extension at 72°C for 1 min. The PCR
products were digested with 8 U of Nco I at 37°C for 6 h.
Digested DNA was analyzed on 8% polyacrylamide gels.
Ethidium bromide staining of the gel demonstrated the
original 782 basepairs fragment (homozygous patients for
allele LTα + 252A), three fragments of 782, 586 and 196
basepairs (heterozygous patients), or two fragments of 586
and 196 basepairs of size (homozygous patients for
the allele LTα + 252 G).
Assay of human leukocyte elastase activity
The method is based on the ability of neutrophil elas-
tase to interact with specific chromogenic substrate
N-methoxysuccinyl-ala-ala-pro-val p-nitro anilide (Sigma,
St Louis, MO, USA), forming a colored complex with
maximum of absorbance at 410 nm [16]. The standard
assay was performed as described earlier [17]. Finally, the
value of neutrophil elastase activity was normalized to the
protein content in each sample of the sputum extract.
Bone density assessment
Fifty four patients were undergone to bone mineral density
(BMD, g/cm2) assessment. BMD was assessed at thelumbar spine (L1-L4) by dual energy x-ray absorptiometry
using a Lunar Prodigy Bone Densitometer (GE Lunar
Corporation, WI, USA). The results were expressed as Z
score for age, sex and ethnicity according to the reference
data given by the GE Lunar Corporation software. Z scores
were calculated by subtracting the sex- and age-specific
population mean BMD from the CF subject’s BMD; this
value was then divided by the standard deviation (SD) of
the sex and age-specific mean. Z scores were classified
according to the standards recently proposed for pediatric
subjects to define bone density reduction [18]. We consi-
dered normal BMD a lumbar spine Z score above −1, mild
BMD reduction a lumbar spine Z score lower than −1.0
but higher than −2, severe BMD reduction a lumbar spine
Z score lower than −2.0.
Statistical analysis
The differences in allele/genotype frequencies between
patients and controls were analyzed by the Fisher’s exact
test. This test was also used for assessment of the diffe-
rences in clinical course between patients with different
genotypes. The levels of neutrophil elastase activity in
sputa, the data of pulmonary function tests as well as
z-score values were compared by unpaired Student’s
t-test. P values less than 0.05 were considered significant.
Ethics approval
The study was approved by the Ethics Committee of the
Research Centre for Medical Genetics.
Results
There were no significant differences between CF patients
and healthy subjects for the TNF genotype frequencies
(Table 1). In order to evaluate the contribution of indivi-
dual polymorphisms in the disease progression, we pooled
the findings about TNF-α and LT-α genes. In spite of such
integration no significant differences between CF patients
and general population of Moscow residents have been
found (Additional file 3: Table S3). We also did not reveal
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distribution (see Additional file 1: Table S1).
Associations with lung diseases
Followed the classical single polymorphism approach,
we have found no association between individual LT-α
or TNF-α single SNPs and lung function in our CF cohort
(Additional file 2: Table S2) but neutrophil elastase activity
was higher in sputum specimens from carriers of geno-
types TNF-α–308GA or LT-α + 252GG, associated with
increased TNF-α production (Figure 1). In the same time
the patients with genotype TNF-α-308GA – LT-α + 252AA
did have a better lung function compared to subjects from
other TNFα – LT-α genotype groups (Table 2). The groups
did not differ significantly in term their age (mean values
ranged from 11.2 to 13.1 years) or P. aeruginosa infection
(from 58.3 to 75% patients in the groups were chronically
colonized with the pathogen).
It was also shown that the carriers of the TNF-α–308A
allele more frequently had asthma as compared to patients
homozygous for the TNF-α–308 G allele (Table 3). These
data are in line with the results of other studies including
meta-analysis [19] suggesting a strong positive association
between –308A allele of TNF-α gene and asthma develop-
ment. In Russian Federation the prevalence of asthma
ranges from 2.2% to 7% in adults and 10% in children
[20]. So, in theory, these proportions of CF pediatric
patients would be expected to have concomitant asthma.
In our CF cohort 7.5% of patients had asthma diagnosis.
We did not find any association between TNF-α–308
polymorphism and tuberculosis susceptibility (see Table 3).
However, in 9 of 108 (8.3%) of LT-α + 252AA carriers tuber-
culosis infection has been documented. At the same time
there was no case of tuberculosis among patients, both
homozygous and heterozygous for LT-α + 252 G alleles
(p = 0.01) (see Table 3). The results are similar to the recent
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Figure 1 Sputum elastase levels in carriers of different TNF-α
-308 and LT-α +252 genotypes among cystic fibrosis patients.have had significantly high frequency of the LT-α + 252A
allele compared to groups of tuberculosis patients [21].
Associations with CF related liver diseases
Liver disease is the second leading cause of death in
patients with CF [22]. It is estimated that 40% of CF
patients develop liver disease, characterized by focal portal
fibrosis and cholestasis, but only 1-5% of these cases
progress to portal hypertension and end-stage liver disease
[23,24]. In our study 14 of 198 patients (7.1%) had severe
cirrhosis with portal hypertension. There were no signifi-
cant association of the cirrhosis development with both
TNF-α–308 G/A or LT-α + 252A/G gene polymorphisms.
In the same time, as can be seen in Table 4, genotypes
TNF-α–308GG – LT-α + 252AA and TNF-α–308GA – LT-
α + 252AG were unfavorable with regard to liver disease
but appeared to have little if any effect on susceptibility to
portal hypertension development. Thus, 25.8% patients
exhibiting genotypes TNF-α–308GA – LT-α + 252AG and
31% patients having TNF-α–308GG – LT-α + 252AA
demonstrated ultrasound signs of cirrhosis development
whereas the frequencies of portal hypertension in these
two groups were 6.2% and 13.8%, respectively. The data
did not differ from those in CF patients with other TNF
genotypes (Additional file 4: Table S4). Similarly, Suneetha
et al. have shown that the combination TNF-α–308GG –
LT-α + 252AA was more common among HBV infected
patients with severe liver disease than those with
mild disease on the basis of histological activity
index and fibrosis score [25]. In our CF cohort 9 of
198 (4.5%) patients were chronically infected with hepatitis
viruses (5 patients - with HCV and 4 subjects - with HBV).
Among them there was only one patient who developed se-
vere liver disease with portal hypertension. As can be seen
in Table 3, LT-α + 252A/G gene polymorphism (but not
TNF-α–308 G/A) was associated with susceptibility to virus
hepatitis in our CF patients. Indeed, among LT-α + 252 G
carriers the patients with virus hepatitis have not been
found, and only patient with LT-α + 252 G/G genotype were
infected with HCV. Our data are in line with previous study
by Goyal et. al. suggesting that LT-α + 252AA allele is
significantly more common in non-CF subjects infected
with HCV as compared to healthy controls [26].
Associations with osteoporosis
Mean lumbar spine BMD Z score in CF patients homo-
zygous for the TNF-α–308G allele was significantly
higher than that in CF carriers of the TNF-α–308A allele
(−1.6 ± 0.3 vs −3.0 ± 0.5, p = 0.027). Bone status of the two
groups is shown in Figure 2. Median age of patients was
not statistically differed in these two groups. Sixteen of 41
patients (39.0%, 11 males and 5 females) homozygous for
the TNF-α–308G allele had a normal BMD, with a Z score
higher than −1. A mild BMD reduction (with lumbar spine
Table 2 Contribution of individual TNF-α and LT-α gene polymorphisms in CF lung disease progression
TNF genes FVC p* FEV1 p*
TNF-α-308GA – LT-α + 252AA 96.9 ± 9.5 (n = 12) 91.5 ± 10.4 (n = 12)
TNF-α-308GG – LT-α + 252AA 78.8 ± 2.6 (n = 94) 0.025 70.3 ± 2.8 (n = 94) 0.015
TNF-α-308GA – LT-α + 252AG 72.5 ± 4.2 (n = 27) 0.008 66.4 ± 5.5 (n = 27) 0.009
TNF-α-308GG – LT-α + 252AG 78.1 ± 3.8 (n = 33) 0.025 72.6 ± 4.6 (n = 32) 0.027
TNF-α-308GG – LT-α + 252GG together withTNF-α-308GA – LT-α + 252GG 76.1 ± 6.8 (n = 11) 0.029 69.3 ± 8.9 (n = 11) 0.039
Boldface shows the favorable genotype in term of CF lung disease progression.
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec.
* comparison with TNF-α-308GA – LT-α + 252AA genotype.
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mented in 12 subjects (29.3%, 5 males and 7 females). A
condition of severe BMD reduction, with a lumbar spine Z
score less than −2, was evident in 13 patients (31.7%,
6 males and 7 females). At the same time 10 of 13
TNF-α–308A carriers (76.4%, 4 males and 6 females)
demonstrated a severe BMD reduction. It was also
shown the statistically significant differences in bone
density among patients homozygous for LT-α + 252A
allele and LT-α + 252 G carriers. The last were found
to demonstrate decreased values of lumbar spine BMD Z
score (−2.5 ± 0.4 vs – 1.5 ± 0.3, p = 0.048) and increased
osteoporosis frequency. Thus, 15 of 24 CF patients (62.5%,
8 males and 7 females) with LT-α + 252 G had severe
BMD reduction. In this patient group a mild BMD reduc-
tion and normal BMD were found in 4 (16.7%) and 5
(20.8%) subjects, respectively. In contrast, most of 30
patients homozygous for LT-α + 252A allele had normal
BMD or mild BMD reduction (11 and 10 individuals,
respectively). No statistical difference was found among
the groups in terms of patient age.Table 3 Frequencies of concomitant diseases in CF
patients with different TNF-α and LT-α gene
polymorphisms
Genotype Asthma Tuberculosis Virus hepatitis
TNF-α–308 GG 5.8% 5.0% 6.3%
(n = 145) (8/145) (7/140) (8/143)
TNF-α–308GA 14.0% 2.9% 3.8%
(n = 53) (7/53) (2/51) (2/53)
P-value 0.068 0.94 0.9
LT-α + 252AA 6.5% 8.3% 6.4%
(n = 110) (7/110) (9/108) (7/109)
LT-α + 252GA 7.8% 0% 0%
(n = 67) (5/67) (0/65) (0/65)
LT-α + 252GG 10.0% 0% 16.7%
(n = 12) (1/12) (0/11) (1/12)
P value PA/A,G/A = 0.013 PA/A,G/A = 0.035
PA/A,G/G+G/A = 0.007 PA/A,G/G+G/A = 0.088Discussion
Many studies have investigated the potential role of TNF-α
and LT-α gene polymorphisms in the development of vari-
ous diseases [19,21,26-30]. Several lines of evidence suggest
that TNF genes may be implicated in the pathogenic
mechanisms of inflammatory diseases. In case of CF we
could say only about CF progression and development of
the disease complications, but not about predisposition to
suffer from CF, since the etiology of it is absolutely
clear and associated with mutation in both CFTR
alleles. It might be supposed that the influence of
TNF gene polymorphisms upon the disease progression in
CF patients is associated with high or low TNF production
in the carriers of different TNF genotypes. Indeed, it was
shown that allele TNF-α–
308A has been associated with higher inducible levels of
gene transcription and TNF-α protein production [27,31].
Among the polymorphisms of LT-α gene LT-α + 252 G
allele is associated with higher TNF-α and TNF-β produc-
tion [10,11]. Clinical observations indirectly confirm the
data received in in vitro experiments on human cell lines.
Thus, the results of meta-analysis carried out to
explore the association between the TNF-α –308GA
polymorphism and asthma development suggested
that TNF-α –308A allele may be a risk factor in the
etiology of the disease. In the subgroup analysis by
atopic status, significant elevated risks of asthma were
associated with A allele carriers in atopic population
[19]. It was also shown that the risk for the –308A
allele in asthma was greater in females [28]. On the con-
trary the TNF-α–308GG genotype may have a protective
role in asthma pathogenesis [29]. At the same time, highly
conserved ancestral haplotype (AH) 8.1 including among
others TNF-α–308A and LT-α + 252 G alleles, is an im-
portant genetic modifier of lung disease in CF. Although
8.1 AH is associated with delayed onset of respiratory
colonization with S. aureus and P. aeruginosa in young CF
patients. An elevated inflammatory response being benefi-
cial in the early stages of childhood CF becomes destruc-
tive as chronic infection ensure in older patients [32]. On
the contrary, primary biliary cirrhosis is associated with
reduced carriage of the high production TNF-α–308A
Table 4 Contribution of individual TNF-α and LT-α gene polymorphisms in CF associated liver disease
TNF genes Cirrhosis (total) p* p** Cirrhosis (without PH) p* p**
TNF-α-308GA–LT-α + 252AA 1/13 (7.7%) 0.061 0.018 0/13 0.028 0.016
TNF-α-308 G–LT- + 252AA 31/97 (32%) — >0.1 25/97 (25.8%) — >0.1
TNF-α-308GA–LT- + 252AG 13/29 (44.8%) >0.1 — 9/29 (31.0%) >0.1 —
TNF-α-308GG–LT- + 252AG 5/37 (13.5%) 0.023 0.005 4/37 (10.8%) 0.045 0.041
TNF-α-308GG–LT- + 252GG together with 2/12 (16.7%) >0.1 0.087 0/12 0.036 0.029
TNF-α-308GA–LT- + 252GG
Boldface shows the unfavorable genotype in term of CF associated liver disease progression.
PH, portal hypertension.
* comparison with TNF-α-308GG – LT-α + 252AA.
** comparison with TNF-α-308GA – LT-α + 252AG.
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TNF-α against the disease. In whole, it is safe to say that
TNF-α is a potent immunomediator and pro-inflammatory
cytokine that has been implicated in the pathogenesis of a
large number of human diseases.
Our data received in the cohort of CF patients confirm
these observations. Thus, the carriers of genotypes,
which are associated with higher TNF production,
demonstrated more frequency of asthma, higher levels
of neutrophil elastase, and decrease of bone density. At
the same time, low TNF producers showed a higher fre-
quency of tuberculosis infection. We believe that the CF
complications associated with TNF gene polymorphismsFigure 2 Frequency of the bone mineral density decrease in carriers o
fibrosis patients.are the same that TNF gene associated diseases in gen-
eral population. Simply, there is a strong possibility that
such genetically predisposed diseases will be diagnosed
in CF subjects in time since most of them undergo a
medical examination at least twice a year.Conclusions
The work shows that the carriers of genotypes, which are
associated with higher TNF production, demonstrate more
frequency of asthma, higher levels of neutrophil elastase,
and decrease of bone density. On the contrary, the carriers
of genotypes associated with low TNF production show af different TNF-α -308 and LT-α +252 genotypes among cystic
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tion. Thereby,TNF genotyping may be useful for prognosis
and for choice of therapeutic strategy in CF patients.
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